Detalles de la búsqueda
1.
Potential for Maternally Administered Vaccine for Infant Group B Streptococcus.
N Engl J Med
; 389(3): 215-227, 2023 Jul 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37467497
2.
Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy.
N Engl J Med
; 386(17): 1615-1626, 2022 04 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35476650
3.
Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.
N Engl J Med
; 386(25): 2377-2386, 2022 06 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-35731653
4.
Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine.
J Infect Dis
; 225(12): 2056-2066, 2022 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34931667
5.
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine.
J Infect Dis
; 225(12): 2077-2086, 2022 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34637519
6.
A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine.
J Infect Dis
; 225(8): 1357-1366, 2022 04 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-34932102
7.
Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.
Clin Infect Dis
; 75(3): 390-398, 2022 08 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-34940806
8.
Carrier-Induced Hyporesponsiveness to Pneumococcal Conjugate Vaccines: Unraveling the Influence of Serotypes, Timing, and Previous Vaccine Dose.
Clin Infect Dis
; 72(3): 448-454, 2021 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31995183
9.
Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age.
Clin Infect Dis
; 73(7): e1489-e1497, 2021 10 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32716500
10.
Proof-of-concept calculations to determine the health-adjusted life-year trade-off between intravitreal anti-VEGF injections and transmission of COVID-19.
Clin Exp Ophthalmol
; 48(9): 1276-1285, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32902023
11.
Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
N Engl J Med
; 372(12): 1114-25, 2015 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-25785969
12.
Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).
Clin Infect Dis
; 65(5): 787-795, 2017 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29017280
13.
Bacteria identified on corneal scrapes demonstrate increasing resistance to fluoroquinolones in New Zealand.
Clin Exp Ophthalmol
; 50(3): 352-354, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35195336
14.
Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae.
J Infect Dis
; 211(7): 1144-53, 2015 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25355940
15.
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.
J Infect Dis
; 212(1): 18-27, 2015 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25395187
16.
Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study.
Clin Infect Dis
; 61(3): 313-23, 2015 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25870329
17.
Multicenter surveillance of Streptococcus pneumoniae isolates from middle ear and mastoid cultures in the 13-valent pneumococcal conjugate vaccine era.
Clin Infect Dis
; 60(9): 1339-45, 2015 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25648240
18.
13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
Pediatr Blood Cancer
; 62(8): 1427-36, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25810327
19.
A Phase 3, Single-arm Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through <18 Years of Age.
Pediatr Infect Dis J
; 43(6): 574-581, 2024 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38502894
20.
A Phase Three Study of the Safety and Immunogenicity of a Four-dose Series of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.
Pediatr Infect Dis J
; 43(6): 596-603, 2024 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38535409